Used in the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). It is a prodrug that converts to the active form, tedizolid, inhibiting bacterial protein synthesis by binding to the 50S ribosomal subunit. Also shows potent activity against vancomycin-resistant enterococci (VRE). Being investigated for use in respiratory tract infections where conventional antibiotics fail. Its phosphate ester form improves oral bioavailability, making it suitable for outpatient therapy.